Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple endocrine neoplasia type I.

Rasa Zarnegar1, Laurent Brunaud, Orlo H Clark

  • 1University of California San Francisco/Mount Zion Medical Center, 1600 Divisadero Street, Box 1674, 94143-1674, USA.

Current Treatment Options in Oncology
|June 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgery is no longer the only effective treatment for obesity: What does this means?

Journal of visceral surgery·2026
Same author

Predicting Best Performers After Minimally Invasive Left Pancreatectomy: Insights From a National Cohort.

Annals of surgery·2026
Same author

Acylcarnitines Are Associated with Metabolic Syndrome and Hypertension in Two Contrasted Obese Populations.

Nutrients·2026
Same author

French expert consensus statement on diagnosis and management of primary hyperparathyroidism.

Annales d'endocrinologie·2025
Same author

Cellular mechanisms of hormone secretion in neuroendocrine tumors: what goes wrong?

Frontiers in cell and developmental biology·2025
Same author

Association Between Surgeon Age and Patient Hemodynamic Instability in Pheochromocytoma Surgery: A Multicenter Cohort Study.

Journal of patient safety·2025
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Multiple endocrine neoplasia type I (MEN1) is a rare genetic disorder. Early screening and surgical intervention for hyperparathyroidism, pituitary, and enteropancreatic tumors are recommended to improve disease-free survival.

Area of Science:

  • Endocrinology
  • Genetics
  • Oncology

Background:

  • Multiple endocrine neoplasia type I (MEN1) is a rare autosomal dominant disorder.
  • Common manifestations include hyperparathyroidism, islet cell tumors, and pituitary tumors.
  • Treatment and screening strategies for MEN1 manifestations lack consensus due to limited large-scale data.

Purpose of the Study:

  • To advocate for early screening and outline therapeutic approaches for MEN1.
  • To provide guidance on managing specific endocrine and nonendocrine tumors associated with MEN1.
  • To address controversies in MEN1 management and highlight institutional practices.

Main Methods:

  • Early screening using biochemical and radiographic testing for patients with MEN1 predisposition.

Related Experiment Videos

  • Surgical intervention for hyperparathyroidism (parathyroid gland resection and thymectomy).
  • Management strategies for pituitary, enteropancreatic, carcinoid, and adrenal tumors, as well as skin lesions.

    • Main Results:

    • Surgical intervention for hyperparathyroidism can lead to disease-free survival up to 30 years, despite high recurrence rates.
    • Prolactinomas are typically managed pharmacologically; growth hormone-releasing tumors surgically.
    • Enteropancreatic tumors and carcinoid tumors warrant surgical or medical treatment based on hormone secretion and early intervention, respectively.

    Conclusions:

    • Early screening and prompt surgical intervention are crucial for managing MEN1 manifestations.
    • Tailored treatment approaches for specific tumors (pituitary, pancreatic, carcinoid) are essential.
    • While challenges exist, proactive management can improve long-term outcomes for MEN1 patients.